Main menu

NCM 2022: Rapid genomic analysis for thrombotic microangiopathy using nanopore adaptive sampling with EPI2ME SeqOne framework


Thrombotic microangiopathy (TMA) encompasses various genetically driven diseases. The highly repetitive character of sequences in this region makes it difficult to detect structural variants when using standard short-read sequencing methods. To implement a versatile, fast-track genomics analysis for TMA in adult renal disease at the Sorbonne University, ICU, we developed a framework using nanopore adaptive sampling coupled to the SeqOne platform for analysis. SeqOne provides a centralised cloud-based solution that includes a nanopore-validated pipeline derived from the EPI2ME framework. This new approach maximizes the chance of discovering new descriptions related to SNVs and SVs and could enable precision medicine for complement-mediated TMA in less than three days for targeted therapy.

Authors: Laurent Mesnard

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

ナノポア技術

ナノポアの最新ニュースを購読 リソースと発表文献 Nanopore Communityとは

Oxford Nanoporeについて

ニュース 会社沿革 持続可能性 経営陣 メディアリソース & お問い合わせ先 投資家向け パートナー向け Oxford Nanopore社で働く 現在の募集状況 営業上の情報 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Japanese flag